The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

More information: Thomas A. Hope et al, SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET, Journal of Nuclear Medicine (2024). DOI: 10.2967/jnumed.124.269002 ...

Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round.

Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505-12.Loktev A, Lindner T, ...

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review" report has been added to ResearchAndMarkets.com's offering.

This is ideal; fibroblast activation protein receptors must be expressed briefly as longer expression may harm other tissues. Results The research team assessed the efficacy of the CAR T cells in ...

LuMIERE is a Phase 1/2 study evaluating FAP-2286 as a peptide-targeted radionuclide therapy (PTRT) targeting fibroblast activation protein, or FAP, in patients with advanced solid tumors ...

The procedure standard/practice guideline outlines several oncologic indications for FAP PET imaging, including gastro-intestinal adenocarcinoma, pancreatic ductal adenocarcinoma, esophageal, head ...